Topical Steroid Withdrawal (TSW): Symptoms, Evidence and What We Know
Current evidence on topical steroid withdrawal
Topical steroid withdrawal, or TSW, describes a severe skin reaction reported after reducing or stopping topical corticosteroids, usually after prolonged or repeated exposure. Research has advanced substantially in 2025 and 2026, but diagnosis can still be difficult because TSW can overlap with recurrent eczema, allergic contact dermatitis and infection.
Quick reference: what we know about TSW
| Question | Current evidence | What this means | Source |
|---|---|---|---|
| Is TSW recognized? | Recognition has increased among researchers and regulatory bodies | The condition is now being studied more directly than in earlier years | PMID 41924752 |
| Common symptoms | Burning, itching, erythema, desquamation and skin hypersensitivity are commonly reported | Symptoms can be severe but overlap with other inflammatory skin disorders | PMID 42170112 |
| Who appears most represented in published cases? | Adult women using topical corticosteroids for atopic dermatitis, often on the face | This describes the current literature, not every person who may develop TSW | PMID 42170112 |
| Is there a validated universal diagnostic test? | No | Diagnosis still relies on history, clinical features and exclusion of look-alike conditions | Current review literature |
Common symptoms described in TSW
The 2026 systematic review found burning in 89.8% of reported cases, itching in 85.6%, skin hypersensitivity in 82.3%, erythema in 89.6% and desquamation in 88.7% across the included literature. PMID 42170112
Other descriptions include flushing, heat or temperature dysregulation, swelling, oozing, sleep disruption and severe discomfort. A 2025 NIH pilot study identified burning, flushing and thermodysregulation as features that may help distinguish a TSW phenotype from ordinary atopic dermatitis. PMID 40088241
What newer research has added
2025 NIH mechanistic study
The NIH-led pilot study examined 16 people fitting proposed TSW criteria and reported both clinical and molecular findings. Researchers identified elevated mitochondrial NAD+ and explored neuroinflammatory mechanisms in skin and laboratory models. PMID 40088241
What this means: TSW research is beginning to move beyond case descriptions toward measurable biological differences, although larger studies are still needed.
2026 review of the controversy
Myles and Ratley summarized the growing recognition of TSW, including clinician consensus work, pilot mechanistic research and regulatory attention. They also note that debate continues over how clearly TSW can be separated from the underlying skin diseases that led to topical steroid use. PMID 41924752
2026 updated systematic review
Choi and colleagues reviewed seven newer studies. Five were case reports, one was a case series and one was a qualitative cross-sectional survey. The review found that inconsistent diagnostic criteria and largely descriptive evidence still make diagnosis and treatment difficult. PMID 42170112
Why diagnosing TSW is difficult
There is no single laboratory test that confirms TSW. Clinicians have to combine the history of topical corticosteroid exposure with the timing and distribution of symptoms, then consider competing explanations such as recurrent eczema, allergic contact dermatitis, infection or rosacea-like reactions.
The 2026 systematic review emphasized that inconsistent definitions and diagnostic criteria remain one of the biggest weaknesses in the literature. This is important because poor diagnostic consistency makes it harder to compare studies, estimate frequency or know which treatments work best. PMID 42170112
TSW vs recurrent eczema or another diagnosis
A severe flare after reducing topical corticosteroids is not automatically TSW. Recurrent atopic dermatitis, allergic contact dermatitis, infection, rosacea-like reactions and undertreated eczema can overlap with the same symptoms.
Useful clues include the steroid history, potency, body sites, duration and frequency of use, whether burning and flushing are prominent, whether the reaction extends beyond previous treatment areas and whether there are signs of infection or contact allergy.
Who appears most represented in current TSW literature?
The 2026 systematic review found that the published cases it analyzed were predominantly adult women using topical corticosteroids for atopic dermatitis, frequently on the face and often involving higher-potency or longer-term exposure. PMID 42170112
What this means: these patterns help identify where the current evidence is concentrated, but they should not be turned into a rule that TSW only occurs in one sex, one age group or one body site.
Topical corticosteroids still have an established role
TSW should not be interpreted to mean that all topical corticosteroid use is unsafe. The American Academy of Dermatology continues to strongly recommend topical corticosteroids for atopic dermatitis, alongside moisturizers, topical calcineurin inhibitors and newer non-steroid therapies. AAD guideline
Risk depends on potency, body site, duration and pattern of use. Appropriate topical corticosteroid treatment and TSW are therefore related topics, but not the same question.
What to do if you suspect TSW
- Document your topical steroid history: product name, potency, body sites, frequency and duration.
- Get the diagnosis reviewed: especially if the reaction is severe, spreading or different from previous eczema.
- Ask about steroid-sparing options: current eczema care includes calcineurin inhibitors, PDE-4 inhibitors, JAK inhibitors, AhR medicines and systemic treatments depending on severity.
- Keep skincare simple during highly reactive periods: introducing many new products at once can make irritation harder to interpret.
- Address pain, sleep and mental-health impact: severe burning and insomnia can be major parts of the illness burden.
Where a steroid-free botanical topical fits
QICAOGANGMU's declared formula contains no corticosteroid. Its ingredients also have separate research involving itch, cooling sensation, inflammation and topical sensory effects.
Review the ingredient and testing evidenceHow long does TSW last?
There is no reliable universal timeline. Published reports describe highly variable courses, and the current evidence is not strong enough to predict an individual's duration from steroid potency, duration or body site alone.
This uncertainty is one reason fixed internet timelines such as "three months" or "one year" should not be treated as medical rules.
Frequently asked questions
Is TSW real?
TSW is increasingly recognized and studied, with newer research describing both clinical features and possible biological mechanisms. At the same time, diagnostic criteria and treatment evidence are still developing.
Can TSW look like eczema?
Yes. There can be substantial overlap, which is why history and clinical assessment matter.
Should everyone stop topical steroids suddenly?
No. Changes to prescribed treatment should reflect the diagnosis, potency, body site and treatment history rather than a general internet rule.
Can antihistamines stop TSW itch?
Itch in TSW may involve pathways beyond histamine, so response can vary. Symptom management should be individualized.
Related articles
Clinical references
- Myles IA, Ratley G. Topical steroid withdrawal: dissecting the controversy. Frontiers in Medicine. 2026. PMID 41924752
- Choi H et al. An Updated Systematic Review of Topical Corticosteroid Withdrawal. Cureus. 2026;18(4):e107365. PMID 42170112
- Shobnam N et al. Topical Steroid Withdrawal Is a Targetable Excess of Mitochondrial NAD+. Journal of Investigative Dermatology. 2025. PMID 40088241
- American Academy of Dermatology. Atopic dermatitis clinical guideline. AAD guideline